SARS CoV 2 News and Research

RSS

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.

19 May 2021

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mediated by the fusion of the spike protein to nearby healthy cells. New research by German researchers sheds light on how this happens.

19 May 2021

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Researchers in the UK say the latest round of the REal-time Assessment of Community Transmission-1 (REACT-1) study has found that the prevalence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – has fallen by 50%, compared with the previous round conducted in March of this year (2021).

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

AMP and APC urge congress to pass the VITAL Act

The Association for Molecular Pathology (AMP) and the Association of Pathology Chairs (APC) commend U.S. Senator Rand Paul (R-KY) for introducing legislation that would allow molecular pathology professionals to continue advancing and offering high-quality laboratory developed testing procedures (LDPs) for patient care.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

A study of immune-deficient adults and children has shown that patients who fail to respond positively to infections and vaccinations have robust humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structural proteins.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

Prior dengue infection considerably increases risk of symptomatic COVID-19

18 May 2021

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19.

18 May 2021

New COVID-19 testing technology is a cheaper, faster alternative to tube-based RT-PCR tests

Throughout the COVID-19 pandemic, supply chain shortages of reagents and test kits have limited the rapid expansion of clinical testing needed to contain the virus.

18 May 2021

New imaging technique helps reveal the best antibodies for COVID-19 detection

Vaccines are turning the tide of the pandemic, but the risk of infection is still present in some situations. If you want to visit a friend, get on a plane, or go see a movie, there is no highly accurate, instant test that can tell you right then and there whether or not you have a SARS-CoV-2 infection.

18 May 2021

New coronavirus test can get fast, accurate results from saliva samples

A new coronavirus test can get accurate results from a saliva sample in less than 30 minutes, researchers report in the journal Nature Communications.

18 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

A possible human-to-canine transmission of SARS-CoV-2

Now, researchers at the U.S. Centers for Disease Control and Prevention (CDC) identified a case of human to animal transmission when SARS-CoV-2 was detected in a healthy poodle dog living with four family members who had COVID-19.

18 May 2021

SARS CoV 2 News and Research

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

AMP and APC urge congress to pass the VITAL Act

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Prior dengue infection considerably increases risk of symptomatic COVID-19

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

New COVID-19 testing technology is a cheaper, faster alternative to tube-based RT-PCR tests

New imaging technique helps reveal the best antibodies for COVID-19 detection

New coronavirus test can get fast, accurate results from saliva samples

SpaceX study profiles evolution of antibody response during COVID-19 infection

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A possible human-to-canine transmission of SARS-CoV-2

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News